PharmaLundensis AB (XSAT:PHAL) Growth Rank : 0 (As of Jun. 10, 2024)

View and export this data going back to 2010. Start your Free Trial

What is PharmaLundensis AB Growth Rank?

PharmaLundensis AB has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

PharmaLundensis AB Growth Rank Related Terms

Thank you for viewing the detailed overview of PharmaLundensis AB's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaLundensis AB (XSAT:PHAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaLundensis AB (XSAT:PHAL) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

Medicon Village, Scheelevagen 2, Lund, SWE, 22381

Website

http://www.pharmalundensis.se

PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology.

PharmaLundensis AB (XSAT:PHAL) Headlines

No Headlines